Brief: LAVA Therapeutics to Present Initial Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma at 2022 ASCO Annual Meeting
01/06/2022 12:50
June 1 (Reuters) - LAVA Therapeutics NV LVTX.O :
* LAVA THERAPEUTICS TO PRESENT INITIAL PHASE 1/2A CLINICAL
TRIAL
DOSE ESCALATION DATA OF LAVA-051 IN CHRONIC LYMPHOCYTIC LEUKEMIA
AND MULTIPLE MYELOMA PATIENTS AT 2022 AMERICAN SOCIETY OF
CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
Source text for Eikon: ID:nGNXywHxY
Further company coverage: LVTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LAVA Therapeutics NV
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 07:29 PM
Brief: Xoma Royalty Announces Closing Of Transactions To Acquire Lava Therapeutics N.V.
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM